{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T21:59:36Z","timestamp":1780437576692,"version":"3.54.1"},"posted":{"date-parts":[[2026,5,15]]},"group-title":"Immunology","reference-count":51,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.biorxiv.org\/about\/FAQ#license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,5,15]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                <jats:p>The emergence of the SARS-CoV-2 Omicron BA.2.86 subvariant, a lineage derived from the BA.2 strain, led to the 2024-2025 COVID-19 vaccine update to include KP.2 or related JN.1-lineage spike antigens. We evaluated the magnitude, breadth, and durability of humoral immune responses following a single KP.2 vaccine dose in a longitudinal cohort of 21 individuals up to six months. KP.2 vaccination increased spike-specific binding and neutralizing antibodies against the ancestral WA1 strain, alongside the BA.5, XBB.1.5, and KP.2 variants. Power law modeling estimated half-lives for WA1- and KP.2-specific IgG responses at 770 and 248 days, respectively. Additionally, the KP.2 dose increased IgG1 and IgG4 subclasses more than IgG2 and IgG3 responses to both spike proteins. Serum depletion experiments using WA1 or KP.2 proteins demonstrated most vaccine-elicited antibodies were cross-reactive. Consequently, KP.2 vaccine-induced antibodies retained broad neutralizing activity against recently circulating Omicron subvariants (BA.2.86, KP.3.1.1, XEC, LP.8.1, LF.7, XFG.3.12, PQ.1, BA.3.2.1, and RE.2). Using a live virus neutralization assay, XFG.3.12 showed the greatest reduction in neutralizing titers relative to KP.2 (4.2-fold). In a small subset, an LP.8.1 vaccine dose increased neutralizing activity against the matched variant while maintaining WA1 and KP.2 cross-reactivity, but only modestly increased antibodies to divergent variants BA.3.2.1 and RE.2. Ultimately, these data indicate the KP.2 mRNA vaccine generates durable, cross-reactive responses against current Omicron subvariants. However, ongoing spike evolution impacts neutralization of emerging lineages, highlighting the need for continued viral monitoring and timely vaccine updates.<\/jats:p>\n                <jats:sec>\n                  <jats:title>IMPORTANCE<\/jats:title>\n                  <jats:p>SARS-CoV-2 continues to evolve, raising ongoing concerns about how well updated vaccines protect against emerging variants. This study evaluates antibody responses after KP.2 spike mRNA vaccine dose and shows that a single dose induces durable and broadly cross-reactive immunity against both earlier strains and recently circulating Omicron subvariants. Despite this breadth, reduced neutralizing activity against certain emerging variants indicates that ongoing antigenic changes can impact vaccine induced antibody effectiveness. These findings provide insight into how current vaccines perform over time and highlight the need to track viral evolution and update vaccine antigens to maintain broad protection against severe disease, hospitalization, and death.<\/jats:p>\n                <\/jats:sec>","DOI":"10.64898\/2026.05.13.725047","type":"posted-content","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T03:15:16Z","timestamp":1778901316000},"source":"Crossref","is-referenced-by-count":1,"title":["Immunological imprinting shapes the cross-reactive antibody responses to the KP.2 and LP.8.1 vaccine doses"],"prefix":"10.64898","author":[{"given":"Sanjeev","family":"Kumar","sequence":"first","affiliation":[{"name":"Center for Childhood Infections and Vaccines, Children\u2019s Healthcare of Atlanta, Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA"},{"name":"Emory Vaccine Center, Emory University, Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilin","family":"Lai","sequence":"additional","affiliation":[{"name":"Center for Childhood Infections and Vaccines, Children\u2019s Healthcare of Atlanta, Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA"},{"name":"Emory Vaccine Center, Emory University, Atlanta, GA, USA"},{"name":"Emory National Primate Research Center, Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madison L.","family":"Ellis","sequence":"additional","affiliation":[{"name":"Center for Childhood Infections and Vaccines, Children\u2019s Healthcare of Atlanta, Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA"},{"name":"Emory Vaccine Center, Emory University, Atlanta, GA, USA"},{"name":"Emory National Primate Research Center, Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anamika","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Emory University School of Medicine, Atlanta, GA 30322, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5285-7725","authenticated-orcid":false,"given":"Devyani","family":"Joshi","sequence":"additional","affiliation":[{"name":"Center for Childhood Infections and Vaccines, Children\u2019s Healthcare of Atlanta, Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA"},{"name":"Emory Vaccine Center, Emory University, Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob Vander","family":"Velden","sequence":"additional","affiliation":[{"name":"Center for Childhood Infections and Vaccines, Children\u2019s Healthcare of Atlanta, Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA"},{"name":"Emory Vaccine Center, Emory University, Atlanta, GA, USA"},{"name":"Emory National Primate Research Center, Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana Ziad Abu","family":"Faraj","sequence":"additional","affiliation":[{"name":"Hope Clinic of Emory Vaccine Center, Emory University, Decatur, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia T.","family":"Wimalasena","sequence":"additional","affiliation":[{"name":"Hope Clinic of Emory Vaccine Center, Emory University, Decatur, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramitha R.","family":"Pallavi","sequence":"additional","affiliation":[{"name":"Hope Clinic of Emory Vaccine Center, Emory University, Decatur, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jad","family":"Iriss","sequence":"additional","affiliation":[{"name":"Hope Clinic of Emory Vaccine Center, Emory University, Decatur, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kareem","family":"Bechnak","sequence":"additional","affiliation":[{"name":"Hope Clinic of Emory Vaccine Center, Emory University, Decatur, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sri","family":"Edupuganti","sequence":"additional","affiliation":[{"name":"Emory Vaccine Center, Emory University, Atlanta, GA, USA"},{"name":"Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2512-7919","authenticated-orcid":false,"given":"Nadine","family":"Rouphael","sequence":"additional","affiliation":[{"name":"Emory Vaccine Center, Emory University, Atlanta, GA, USA"},{"name":"Hope Clinic of Emory Vaccine Center, Emory University, Decatur, GA, USA"},{"name":"Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8855-3029","authenticated-orcid":false,"given":"Eric A.","family":"Ortlund","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Emory University School of Medicine, Atlanta, GA 30322, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3031-7194","authenticated-orcid":false,"given":"Alberto","family":"Moreno","sequence":"additional","affiliation":[{"name":"Emory Vaccine Center, Emory University, Atlanta, GA, USA"},{"name":"Emory National Primate Research Center, Atlanta, GA, USA"},{"name":"Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8803-7606","authenticated-orcid":false,"given":"Vineet D.","family":"Menachery","sequence":"additional","affiliation":[{"name":"Center for Childhood Infections and Vaccines, Children\u2019s Healthcare of Atlanta, Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA"},{"name":"Emory Vaccine Center, Emory University, Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika I.","family":"Zarnitsyna","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Emory University, Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1733-4424","authenticated-orcid":false,"given":"Jens","family":"Wrammert","sequence":"additional","affiliation":[{"name":"Center for Childhood Infections and Vaccines, Children\u2019s Healthcare of Atlanta, Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA"},{"name":"Emory Vaccine Center, Emory University, Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2686-8380","authenticated-orcid":false,"given":"Mehul S.","family":"Suthar","sequence":"additional","affiliation":[{"name":"Center for Childhood Infections and Vaccines, Children\u2019s Healthcare of Atlanta, Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA"},{"name":"Emory Vaccine Center, Emory University, Atlanta, GA, USA"},{"name":"Emory National Primate Research Center, Atlanta, GA, USA"},{"name":"Department of Microbiology and Immunology, Emory University, Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2026051905450591000_2026.05.13.725047v1.1","doi-asserted-by":"crossref","unstructured":"Abu-Raddad LJ , Chemaitelly H , Bertollini R , National Study Group for C-V. 2022. Waning mRNA-1273 Vaccine Effectiveness against SARS-CoV-2 Infection in Qatar. N Engl J Med 386:1091\u20131093.","DOI":"10.1056\/NEJMc2119432"},{"key":"2026051905450591000_2026.05.13.725047v1.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035389"},{"key":"2026051905450591000_2026.05.13.725047v1.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034577"},{"key":"2026051905450591000_2026.05.13.725047v1.4","doi-asserted-by":"crossref","first-page":"732690","DOI":"10.3389\/fimmu.2021.732690","article-title":"Angiotensin-Converting Enzyme 2 (ACE2) in the Pathogenesis of ARDS in COVID-19","volume":"12","year":"2021","journal-title":"Front Immunol"},{"key":"2026051905450591000_2026.05.13.725047v1.5","doi-asserted-by":"crossref","first-page":"928279","DOI":"10.3389\/fcimb.2022.928279","article-title":"Broadly Neutralizing Antibodies to SARS-CoV-2 Provide Novel Insights Into the Neutralization of Variants and Other Human Coronaviruses","volume":"12","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"2026051905450591000_2026.05.13.725047v1.6","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04389-z"},{"key":"2026051905450591000_2026.05.13.725047v1.7","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41541-025-01348-x","article-title":"Assessment of SARS-CoV-2 immune escape using antigenic cartography combined with experimental challenge studies","volume":"11","year":"2026","journal-title":"NPJ Vaccines"},{"key":"2026051905450591000_2026.05.13.725047v1.8","doi-asserted-by":"crossref","first-page":"115543","DOI":"10.1016\/j.celrep.2025.115543","article-title":"Antibody evasiveness of SARS-CoV-2 subvariants KP.3.1.1 and XEC","volume":"44","year":"2025","journal-title":"Cell Rep"},{"key":"2026051905450591000_2026.05.13.725047v1.9","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(24)00688-1"},{"key":"2026051905450591000_2026.05.13.725047v1.10","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02517-y"},{"key":"2026051905450591000_2026.05.13.725047v1.11","doi-asserted-by":"crossref","first-page":"eadu8067","DOI":"10.1126\/scitranslmed.adu8067","article-title":"The XBB.1.5 COVID-19 vaccine elicits a durable antibody response to ancestral and XBB.1.5 SARS-CoV-2 spike proteins","volume":"17","year":"2025","journal-title":"Sci Transl Med"},{"key":"2026051905450591000_2026.05.13.725047v1.12","doi-asserted-by":"crossref","first-page":"127997","DOI":"10.1016\/j.vaccine.2025.127997","article-title":"Immunogenicity of JN.1 and KP.2 COVID-19 mRNA vaccines against emerging SARS-CoV-2 variants","volume":"69","year":"2026","journal-title":"Vaccine"},{"key":"2026051905450591000_2026.05.13.725047v1.13","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(25)00007-6"},{"key":"2026051905450591000_2026.05.13.725047v1.14","first-page":"1887","article-title":"Broad immunogenicity to prior SARS-CoV-2 strains and JN.1 variant elicited by XBB.1.5 vaccination in nursing home residents","volume":"47","year":"2025","journal-title":"Geroscience"},{"key":"2026051905450591000_2026.05.13.725047v1.15","doi-asserted-by":"crossref","unstructured":"Cherneha M , Zydek I , Brass P , Korth J , Jansen S , Esser S , Karsten CB , Meyer F , Kraiselburd I , Dittmer U , Lindemann M , Horn PA , Witzke O , Thummler L , Krawczyk A . 2024. Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in People Living with HIV (PLWH). Vaccines (Basel) 12.","DOI":"10.3390\/vaccines12070785"},{"key":"2026051905450591000_2026.05.13.725047v1.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2213948"},{"key":"2026051905450591000_2026.05.13.725047v1.17","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7242e1"},{"key":"2026051905450591000_2026.05.13.725047v1.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113444"},{"key":"2026051905450591000_2026.05.13.725047v1.19","doi-asserted-by":"publisher","DOI":"10.1016\/J.CELL.2021.12.046"},{"key":"2026051905450591000_2026.05.13.725047v1.20","doi-asserted-by":"publisher","DOI":"10.1016\/J.VACCINE.2023.10.051"},{"key":"2026051905450591000_2026.05.13.725047v1.21","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(23)00813-7"},{"key":"2026051905450591000_2026.05.13.725047v1.22","doi-asserted-by":"crossref","first-page":"116440","DOI":"10.1016\/j.celrep.2025.116440","article-title":"Antibody evasion and receptor binding of SARS-CoV-2 LP.8.1.1, NB.1.8.1, XFG, and related subvariants","volume":"44","year":"2025","journal-title":"Cell Rep"},{"key":"2026051905450591000_2026.05.13.725047v1.23","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(24)00298-6"},{"key":"2026051905450591000_2026.05.13.725047v1.24","doi-asserted-by":"crossref","unstructured":"Arunachalam PS , Lai L , Samaha H , Feng Y , Hu M , Hui HS , Wali B , Ellis M , Davis-Gardner ME , Huerta C , Bechnak K , Bechnak S , Lee M , Litvack MB , Losada C , Grifoni A , Sette A , Zarnitsyna VI , Rouphael N , Suthar MS , Pulendran B . 2023. Durability of immune responses to mRNA booster vaccination against COVID-19. J Clin Invest 133.","DOI":"10.1172\/JCI167955"},{"key":"2026051905450591000_2026.05.13.725047v1.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2024.101884"},{"key":"2026051905450591000_2026.05.13.725047v1.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110345"},{"key":"2026051905450591000_2026.05.13.725047v1.27","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06487-6"},{"key":"2026051905450591000_2026.05.13.725047v1.28","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s41586-022-05644-7","article-title":"Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution","volume":"614","year":"2023","journal-title":"Nature"},{"key":"2026051905450591000_2026.05.13.725047v1.29","doi-asserted-by":"crossref","unstructured":"Torresi J , Edeling MA. 2024. Immune imprinting of SARS-CoV-2 responses: changing first immune impressions. mSphere 9:e0075823.","DOI":"10.1128\/msphere.00758-23"},{"key":"2026051905450591000_2026.05.13.725047v1.30","doi-asserted-by":"crossref","first-page":"101291","DOI":"10.1016\/j.xcrm.2023.101291","article-title":"Immune imprinting as a barrier to effective COVID-19 vaccines","volume":"4","year":"2023","journal-title":"Cell Rep Med"},{"key":"2026051905450591000_2026.05.13.725047v1.31","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07539-1"},{"key":"2026051905450591000_2026.05.13.725047v1.32","doi-asserted-by":"crossref","first-page":"veag016","DOI":"10.1093\/ve\/veag016","article-title":"Identification and genomic characterization of BA.3.2: a highly divergent BA.3-related SARS-CoV-2 lineage from southern Africa","volume":"12","year":"2026","journal-title":"Virus Evol"},{"key":"2026051905450591000_2026.05.13.725047v1.33","doi-asserted-by":"publisher","DOI":"10.64898\/2026.02.02.702852:2026.02.02.702852"},{"key":"2026051905450591000_2026.05.13.725047v1.34","doi-asserted-by":"crossref","first-page":"veag011","DOI":"10.1093\/ve\/veag011","article-title":"Evolution and viral properties of the SARS-CoV-2 BA.3.2 subvariant","volume":"12","year":"2026","journal-title":"Virus Evol"},{"key":"2026051905450591000_2026.05.13.725047v1.35","doi-asserted-by":"crossref","first-page":"e212","DOI":"10.1016\/S1473-3099(26)00050-2","article-title":"Overcoming immune imprinting with the COVID-19 LP.8.1 mRNA boosters","volume":"26","year":"2026","journal-title":"Lancet Infect Dis"},{"key":"2026051905450591000_2026.05.13.725047v1.36","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(25)00058-1"},{"key":"2026051905450591000_2026.05.13.725047v1.37","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adj9945"},{"key":"2026051905450591000_2026.05.13.725047v1.38","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abq4130"},{"key":"2026051905450591000_2026.05.13.725047v1.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2024.106317"},{"key":"2026051905450591000_2026.05.13.725047v1.40","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ads1482"},{"key":"2026051905450591000_2026.05.13.725047v1.41","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2025-335375"},{"key":"2026051905450591000_2026.05.13.725047v1.42","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-023-00871-z"},{"key":"2026051905450591000_2026.05.13.725047v1.43","doi-asserted-by":"crossref","unstructured":"Uversky VN , Redwan EM , Makis W , Rubio-Casillas A . 2023. IgG4 Antibodies Induced by Repeated Vaccination May Generate Immune Tolerance to the SARS-CoV-2 Spike Protein. Vaccines (Basel) 11.","DOI":"10.20944\/preprints202303.0441.v1"},{"key":"2026051905450591000_2026.05.13.725047v1.44","doi-asserted-by":"crossref","first-page":"e374","DOI":"10.1016\/S1473-3099(25)00308-1","article-title":"Antigenic and virological characteristics of SARS-CoV-2 variants BA.3.2, XFG, and NB.1.8.1","volume":"25","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"2026051905450591000_2026.05.13.725047v1.45","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/s41392-023-01712-0","article-title":"SARS-CoV-2 Omicron subvariant BA.2.86: limited potential for global spread","volume":"8","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"2026051905450591000_2026.05.13.725047v1.46","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.chom.2021.03.009","article-title":"Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant","volume":"29","year":"2021","journal-title":"Cell Host Microbe"},{"key":"2026051905450591000_2026.05.13.725047v1.47","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2020.04.004"},{"key":"2026051905450591000_2026.05.13.725047v1.48","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1056\/NEJMc2107799","article-title":"Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants","volume":"385","year":"2021","journal-title":"N Engl J Med"},{"key":"2026051905450591000_2026.05.13.725047v1.49","doi-asserted-by":"publisher","DOI":"10.1002\/cpim.116"},{"key":"2026051905450591000_2026.05.13.725047v1.50","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.add2032"},{"key":"2026051905450591000_2026.05.13.725047v1.51","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0006862"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.64898\/2026.05.13.725047","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T12:45:21Z","timestamp":1779194721000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.64898\/2026.05.13.725047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":51,"URL":"https:\/\/doi.org\/10.64898\/2026.05.13.725047","relation":{},"subject":[],"published":{"date-parts":[[2026,5,15]]},"subtype":"preprint"}}